Case reports in oncology · 2026
Long-Term Continuation Therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced Non-Small Cell Lung Cancer: Case Reports and Mechanistic Insights.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Xiaofen, Li Xueying, Liao Jiehao, Chen Suhua, Wang Bo
Аннотация
INTRODUCTION: The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) as long-term continuation therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present 2 cases of advanced NSCLC achieving prolonged progression-free survival with nab-paclitaxel-based regimens.
CASE PRESENTATION: Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6-8 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, ≥3 adverse events), and preserved quality of life.
CONCLUSION: The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.
CASE PRESENTATION: Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6-8 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, ≥3 adverse events), and preserved quality of life.
CONCLUSION: The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.